GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is 34.69.
| Share Price | ₹2,209.8 | Oct 08,2026 |
| Market Cap | ₹62,359.1 Cr | |
| Earnings-TTM | ₹1,797.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 34.69x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹62,359.1 Cr] as on Oct 08,2026
(/) Earnings [ ₹1,797.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 34.69x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay 34.69 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 28.62x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 41.5x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2026 at 44.21x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 1,797.81 | 34.69 | 62,359.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.54 | 420,483.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 85.21 | 249,248.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 82.48 | 177,822.0 |
| CIPLA LTD | 3,364.84 | 31.33 | 105,427.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.08 | 98,492.3 |
| MANKIND PHARMA LTD | 2,055.11 | 48.20 | 99,064.7 |
| LUPIN LTD | 5,551.01 | 16.00 | 88,805.7 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.76 | 111,242.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.45 | 94,477.0 |
| LAURUS LABS LTD | 1,090.76 | 99.07 | 108,062.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.00x |
| Max industry PE | 99.07x |
| Median industry PE | 34.54x |
| Average industry PE | 46.62x |
You may also like the below Video Courses